NRG-GY037
Trial Overview
Official Title
A Phase III study of induction pembrolizumab and chemotherapy followed by pembrolizumab before chemoradiation and pembrolizumab maintenance compared to standard chemoradiation with pembrolizumab followed by pembrolizumab maintenance in high-risk cervical cancer
Study Purpose
To find out if adding an immunotherapy drug plus chemotherapy before starting the usual combination of chemotherapy and radiation will increase overall survival or improve recurrence-free survival from cervical cancer.
Diagnosis
Cervical cancer, squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinomaEligibility
Newly diagnosed, unresected, Stage III or IVA
Patients must sign an approved informed consent and authorization permitting release of personal health information
Intervention
Treatment 1: Chemoradiation + Brachytherapy + Pembrolizumab followed by Maintenance Pembrolizumab for up to 2 years
Treatment 2: Induction Chemotherapy + Pembrolizumab followed by Chemoradiation + Brachytherapy + Pembrolizumab followed by Maintenance Pembrolizumab for up to 2 years
For more information, click the link below:
https://clinicaltrials.gov/study/NCT07061977?term=gy037&rank=1